Lusutrombopag

證據等級: L5

預測適應症: 10 個

Lusutrombopag: From Chronic Liver Disease-Associated Thrombocytopenia to Hereditary Thrombocytopenia with Normal Platelets

One-Sentence Summary

Lusutrombopag is an oral TPO receptor agonist originally used to raise platelet counts before scheduled invasive procedures in patients with chronic liver disease. The TxGNN model predicts it may be relevant to Hereditary Thrombocytopenia with Normal Platelets, but this signal is currently supported by 0 clinical trials and 0 publications — it is a computational prediction only.

Quick Overview

Item	Content
Original Indication	Preoperative thrombocytopenia in chronic liver disease patients (per evidence-pack rationale text; not independently confirmed by a formal indication record)
Predicted New Indication	Hereditary Thrombocytopenia with Normal Platelets
TxGNN Prediction Score	99.995% (rank 88 overall)
Evidence Level	L5 (model prediction only)
Finland Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is flagged as a data gap in the structured record (DG002). Based on the information available in the evidence pack, lusutrombopag is an oral TPO receptor agonist (TPO-RA) that stimulates megakaryocyte proliferation and differentiation to increase platelet production; its approved use is for thrombocytopenia prior to invasive procedures in chronic liver disease.

Hereditary thrombocytopenia with normal platelets is a disorder of platelet production regulation rather than a platelet functional defect, so directionally the TPO-RA mechanism (increasing platelet output) is biologically plausible for this indication. However, this link is inferred purely from TxGNN embedding similarity — there is no clinical trial, registry, or published case evidence connecting lusutrombopag to this condition to date.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Finland Market Information

Lusutrombopag is not currently marketed in Finland — no marketing authorizations are on record, so no product/dosage-form/indication information is available.

Safety Considerations

Please refer to the package insert for safety information. Note: TFDA package insert warnings/contraindications data is currently a blocking data gap (DG001) — a formal S1 safety screening cannot be completed until this is resolved.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction is itself scored as a "Research Question" (S0), with no clinical trial or literature support, and the drug's safety data (TFDA insert) is a blocking gap that prevents even a preliminary safety screen. The other 9 predicted indications in this evidence pack (rank 2–10, including two ALS-spectrum diseases likely reflecting embedding-level false positives) were independently assessed as Hold, reinforcing that this candidate is not yet actionable.

To proceed, the following is needed:

TFDA/manufacturer package insert (resolves DG001 — required before any safety screening)
Confirmed mechanism of action detail (resolves DG002)
Preclinical or mechanistic evidence directly linking TPO-RA pathway activity to hereditary thrombocytopenia with normal platelets
Ongoing literature/trial monitoring, since current PubMed/ClinicalTrials.gov/ICTRP searches all returned zero results
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.